Membranoproliferative glomerulonephritis cost-effectiveness of therapy

Membranoproliferative glomerulonephritis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Membranoproliferative glomerulonephritis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Membranoproliferative glomerulonephritis cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Membranoproliferative glomerulonephritis cost-effectiveness of therapy
CDC on Membranoproliferative glomerulonephritis cost-effectiveness of therapy
Membranoproliferative glomerulonephritis cost-effectiveness of therapy in the news
Blogs on Membranoproliferative glomerulonephritis cost-effectiveness of therapy
Directions to Hospitals Treating Membranoproliferative glomerulonephritis
Risk calculators and risk factors for Membranoproliferative glomerulonephritis cost-effectiveness of therapy

Albeit, there is several strategies for treatment of MPGN, each method has its own indications, however, new medications such as monoclonal antibodies (Rituximab) is demonstrating new path for future treatment of MPGN